{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:44:54Z","timestamp":1787633094238,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.nmd.2019.11.002","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T23:14:33Z","timestamp":1573254873000},"page":"93-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10\u201312, 2019, Hoofdorp, The Netherlands"],"prefix":"10.1016","volume":"30","author":[{"given":"Tamara","family":"Dangouloff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Burghes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo F.","family":"Tizzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Dangouloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Burghes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Boemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Mueller-Felber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Tiziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo F.","family":"Tizzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Germanenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mencia","family":"de Lemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Ouillade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Rucinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wildon","family":"Farwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Gorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Hjort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Kausar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmd.2019.11.002_bib0001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.nmd.2019.11.002_bib0002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","article-title":"Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene","volume":"125","author":"Alias","year":"2009","journal-title":"Hum genet."},{"key":"10.1016\/j.nmd.2019.11.002_bib0003","series-title":"Spinal muscular atrophy","article-title":"Sixty years of spinal muscular atrophy: a personal odyssey","author":"Dubowitz","year":"2017"},{"issue":"1","key":"10.1016\/j.nmd.2019.11.002_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","article-title":"Disease burden of spinal muscular atrophy in Germany","volume":"11","author":"Klug","year":"2016","journal-title":"Orphanet J Rare Dis."},{"issue":"7","key":"10.1016\/j.nmd.2019.11.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data Nathis-Sma study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.nmd.2019.11.002_bib0006","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord."},{"issue":"18","key":"10.1016\/j.nmd.2019.11.002_bib0007","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"New Engl J Med."},{"issue":"1","key":"10.1016\/j.nmd.2019.11.002_bib0008","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","article-title":"SMArtCARE \u2013 a platform to collect real-life outcome data of patients with spinal muscular atrophy","volume":"14","author":"Pechmann","year":"2019","journal-title":"Orphanet J Rare Dis."},{"issue":"14","key":"10.1016\/j.nmd.2019.11.002_bib0009","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.nmd.2019.11.002_bib0010","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 sma infants, children and young adults: preliminary results on motor function","volume":"28","author":"Pane","year":"2018","journal-title":"Neuromuscul Disord."},{"issue":"1","key":"10.1016\/j.nmd.2019.11.002_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol."},{"issue":"11","key":"10.1016\/j.nmd.2019.11.002_bib0012","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromusc Disord"},{"issue":"18","key":"10.1016\/j.nmd.2019.11.002_bib0013","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl Journal Med."},{"key":"10.1016\/j.nmd.2019.11.002_bib0014","doi-asserted-by":"crossref","unstructured":"Dabbous O., Sproule D., Feltner D.E., Ogrinc F.G., Menier M., Droege M., et al. Event-Free survival and motor milestone achievement following AVXS-101 and nusinersen interventions contrasted to natural history for type I spinal muscular atrophy patients. AAN: S25: Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes. 2019.","DOI":"10.1212\/WNL.92.15_supplement.S25.005"},{"key":"10.1016\/j.nmd.2019.11.002_bib0015","doi-asserted-by":"crossref","unstructured":"Servais L., Baranello G., Day J.W., Deconinck N., Mercuri E., A. K., et al. FIREFISH part 1: survival, ventilation and swallowing ability in infants with type 1 SMA receiving Risdiplam (RG7916). AAN: S25: Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes. 2019.","DOI":"10.1212\/WNL.92.15_supplement.S25.008"},{"key":"10.1016\/j.nmd.2019.11.002_bib0016","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment in SMA","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag."},{"key":"10.1016\/j.nmd.2019.11.002_bib0017","unstructured":"FDA. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality: 05\/24\/2019; 2019[Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease."},{"key":"10.1016\/j.nmd.2019.11.002_bib0018","article-title":"Principles and practice of screening for disease","volume":"34","author":"Wilson","year":"1968"},{"issue":"12","key":"10.1016\/j.nmd.2019.11.002_bib0019","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41431-019-0415-4","article-title":"Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors","volume":"27","author":"Serra-Juhe","year":"2019","journal-title":"Eur J Human Genet."},{"key":"10.1016\/j.nmd.2019.11.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of spinal muscular atrophy through newborn screening","volume":"190","author":"Chien","year":"2017","journal-title":"J Pediatr."},{"issue":"6","key":"10.1016\/j.nmd.2019.11.002_bib0021","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot study of population-based newborn screening for spinal muscular atrophy in new york state","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet Med."},{"issue":"5","key":"10.1016\/j.nmd.2019.11.002_bib0022","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","article-title":"Newborn screening for SMA in Southern Belgium","volume":"29","author":"Boemer","year":"2019","journal-title":"Neuromuscul Disord."},{"issue":"3","key":"10.1016\/j.nmd.2019.11.002_bib0023","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am J Hum Genet."},{"issue":"14","key":"10.1016\/j.nmd.2019.11.002_bib0024","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/hmg\/ddx166","article-title":"A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy","volume":"26","author":"Wu","year":"2017","journal-title":"Hum Mol Genet."},{"issue":"3","key":"10.1016\/j.nmd.2019.11.002_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","article-title":"Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype","volume":"138","author":"Ruhno","year":"2019","journal-title":"Hum Genet."},{"issue":"9","key":"10.1016\/j.nmd.2019.11.002_bib0026","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jmg.2010.079004","article-title":"The c.859G>C variant in the SMN2 gene is associated with types II and III sma and originates from a common ancestor","volume":"47","author":"Bernal","year":"2010","journal-title":"J Med Genet."},{"issue":"6","key":"10.1016\/j.nmd.2019.11.002_bib0027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.0000000000007836","article-title":"Discrepancy in redetermination of SMN2 copy numbers in children with SMA","volume":"93","author":"Schorling","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nmd.2019.11.002_bib0028","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.nmd.2019.11.002_bib0029","doi-asserted-by":"crossref","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and neurofilament proteins in health and disease","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1\u20132","key":"10.1016\/j.nmd.2019.11.002_bib0030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"Petzold","year":"2005","journal-title":"J Neurol Sci."},{"issue":"7","key":"10.1016\/j.nmd.2019.11.002_bib0031","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1016\/j.nmd.2019.11.002_bib0032","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.11.002_bib0033","unstructured":"Human N.F.-H. Simple plex assay for the detection of human neurofilament heavy (NF-H) in serum pEH, and cerebrospinal fluid (CSF) [ProteinSimple assay specification sheet]. Available at:https:\/\/www.proteinsimple.com\/documents\/NF-H_Specification_Sheet_Rev_B.pdf. Accessed 20 May 2019."},{"issue":"5","key":"10.1016\/j.nmd.2019.11.002_bib0034","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol."},{"key":"10.1016\/j.nmd.2019.11.002_bib0035","unstructured":"Sumner CJ D.B., Muntoni F., Crawford T.O., Finkel R.S., Mercuri E., De Vivo D.C., et al. Association of phosphorylated neurofilament heavy chain (pNF-H) levels with motor function achievement in individuals with spinal muscular atrophy (SMA) treated with nusinersen. Proceedings of the AAN 2019 \u2013 Seventy-first Annual Meeting, May 4\u201310, 2019, Philadelphia, PA, USA."},{"key":"10.1016\/j.nmd.2019.11.002_bib0036","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2019.11.002_bib0037","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/jnnp-2018-320033","article-title":"Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen","volume":"90","author":"Winter","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.nmd.2019.11.002_bib0038","first-page":"461","article-title":"(S)un (M)ay (A)rise on SMA: l'espoir d'une r\u00e9gion sans amyotrophie spinale [(S)un (M)ay (A)rise on SMA: the hope of a region without spinal muscular atrophy]","volume":"74","author":"Boemer","year":"2019","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.nmd.2019.11.002_bib0039","first-page":"1068","article-title":"High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR","volume":"90","author":"Czibere","year":"2019","journal-title":"Eur J Hum Genet."},{"key":"10.1016\/j.nmd.2019.11.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1177\/1756285618754459","article-title":"Nusinersen for spinal muscular atrophy","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"issue":"2","key":"10.1016\/j.nmd.2019.11.002_bib0041","first-page":"119","article-title":"Diagnostic methods for Lysosomal storage disease","volume":"7","author":"Mokhtariye","year":"2019","journal-title":"Rep Biochem Mol Biol."},{"issue":"2","key":"10.1016\/j.nmd.2019.11.002_bib0042","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2008.05.005","article-title":"Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic fibrosis foundation consensus report","volume":"153","author":"Farrell","year":"2008","journal-title":"J Pediatr."},{"issue":"2","key":"10.1016\/j.nmd.2019.11.002_bib0043","doi-asserted-by":"crossref","first-page":"00109","DOI":"10.1183\/23120541.00109-2017","article-title":"Early diagnosis from newborn screening maximises survival in severe cystic fibrosis","volume":"4","author":"Tridello","year":"2018","journal-title":"ERJ Open Res."},{"issue":"1","key":"10.1016\/j.nmd.2019.11.002_bib0044","article-title":"Screening and genetic diagnosis of hemoglobinopathies in southern and northern europe: two examples","volume":"1","author":"Amato","year":"2009","journal-title":"Mediterr J Hematol Infect Dis."},{"issue":"6","key":"10.1016\/j.nmd.2019.11.002_bib0045","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/humu.22989","article-title":"NGS-Based assay for the identification of individuals carrying recessive genetic mutations in reproductive medicine","volume":"37","author":"Abuli","year":"2016","journal-title":"Hum Mutat."},{"issue":"5","key":"10.1016\/j.nmd.2019.11.002_bib0046","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/cge.12222","article-title":"Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene","volume":"85","author":"Alias","year":"2014","journal-title":"Clin Genet."},{"issue":"2","key":"10.1016\/j.nmd.2019.11.002_bib0047","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/gim.2013.84","article-title":"An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy","volume":"16","author":"Luo","year":"2014","journal-title":"Genet Med."},{"issue":"10","key":"10.1016\/j.nmd.2019.11.002_bib0048","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/s41431-018-0193-4","article-title":"Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling","volume":"26","author":"Alias","year":"2018","journal-title":"Eur J Hum Genet."},{"issue":"7220","key":"10.1016\/j.nmd.2019.11.002_bib0049","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/bmj.319.7220.1293","article-title":"Treatments that fail to prove their worth. interview by Judy Jones","volume":"319","author":"Jonsson","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.nmd.2019.11.002_bib0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0168-8510(97)00901-9","article-title":"The role of economic evaluation in the pricing and reimbursement of medicines","volume":"40","author":"Drummond","year":"1997","journal-title":"Health Policy (New York)"},{"key":"10.1016\/j.nmd.2019.11.002_bib0051","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2015"},{"issue":"9","key":"10.1016\/j.nmd.2019.11.002_bib0052","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nmd.2019.11.002_bib0053","series-title":"Pharmacoeconomic review report: Nusinersen (Spinraza): (Biogen Canada Inc): Indication: Treatment of patients with 5q SMA","year":"2018"},{"key":"10.1016\/j.nmd.2019.11.002_bib0054","unstructured":"ICER. Spinraza\u24c7 and zolgensma\u24c7 for spinal muscular atrophy: effectiveness and value. 2019. Institute for Clinical and Economic Review, www.icer.org 0403192019 i\u2013iii."},{"issue":"6","key":"10.1016\/j.nmd.2019.11.002_bib0055","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","article-title":"Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez","year":"2019","journal-title":"PharmacoEcon."},{"key":"10.1016\/j.nmd.2019.11.002_bib0056","first-page":"795","article-title":"Value-Based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold","volume":"27","author":"Garrison","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.nmd.2019.11.002_bib0057","doi-asserted-by":"crossref","first-page":"253.e1","DOI":"10.1016\/j.ajog.2010.01.032","article-title":"The cost-effectiveness of prenatal screening for spinal muscular atrophy","volume":"202","author":"Little","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.nmd.2019.11.002_bib0058","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ajmg.a.38031","article-title":"Population screening for spinal muscular atrophy: a mixed methods study of the views of affected families","volume":"173","author":"Boardman","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"2","key":"10.1016\/j.nmd.2019.11.002_bib0059","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"10.1016\/j.nmd.2019.11.002_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0000000000006026","article-title":"Precious SMA natural history data: a benchmark to measure future treatment successes","volume":"91","author":"Darras","year":"2018","journal-title":"Neurology"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089661931171X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089661931171X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:08:46Z","timestamp":1760774926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096089661931171X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S096089661931171X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2019.11.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10\u201312, 2019, Hoofdorp, The Netherlands","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}